The Global Industry For Epinephrine Auto Injectors is on a trajectory of robust growth, poised to soar from US$ 2 billion in 2022 to a projected US$ 3.2 billion by 2032, boasting a Compound Annual Growth Rate (CAGR) of 4.9% over the next decade.
This optimistic outlook is fueled by a confluence of factors, with substantial advancements in syringes and injectors playing a pivotal role. Responding to evolving clinical and patient needs, manufacturers have steered the development of epinephrine auto-injectors towards heightened efficacy, safety, and user-friendliness.
The opportunities in the Global Epinephrine Auto Injectors Industry are expanding rapidly. The growing prevalence of allergies among individuals has been a major driver of the market’s growth. The increasing number of people with allergies to dust, insect bites and venom, food, and food additives has contributed to the growth of the Global Epinephrine Auto Injectors Industry.
Moreover, vendor investments in research and development initiatives to create chlorofluorocarbon-free epinephrine auto-injector inhalers using hydrofluoroalkanes as propellants have accelerated the key trends and opportunities in the epinephrine auto-injectors market.
Request a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-14876
However, excessive use of epinephrine can lead to adverse side effects such as cardiac arrhythmia, pulmonary edema, vomiting, and brain hemorrhage, which may pose a challenge for the Global Epinephrine Auto Injectors Industry.
During the forecast period, the regional market for epinephrine auto-injectors is expected to be driven by the increasing number of people suffering from various types of allergies, the availability of low-cost generic epinephrine auto-injectors, and the high adoption rate of epinephrine auto-injectors in the United States. The adoption trends in the epinephrine auto-injector market are also expected to contribute to its growth.
Key takeaways:
- In the United States, the epinephrine auto-injectors market size is estimated to reach US$ 1.2 Billion by 2032, increasing at a CAGR of 4.7% through 2032.
- The epinephrine auto-injectors market share in the United Kingdom is expected to be worth US$ 132.9 Million by 2032, with a CAGR of 3.6% through 2032.
- China’s epinephrine auto-injectors market share is expected to reach US$ 233.7 Million by 2032, with a CAGR of 4.2% through 2032.
- The market share for epinephrine auto-injectors in Japan is expected to be valued US$ 188.5 Million by 2032, expanding at a 3.3% annual rate through 2032.
- South Korea is expected to reach a market size of US$ 117.6 Million in epinephrine auto-injectors by 2032, with a CAGR of 2.8% through 2032.
- The epinephrine auto-injectors market’s Hospitals segment from the end user category is predicted to develop at a CAGR of 4.8% through 2032.
- Through 2032, 0.3 mg sector in the epinephrine auto-injectors market’s dosage category will grow at a CAGR of 4.9%.
Revealing the hidden assumptions of the study. Ask An Analyst Now!
https://www.futuremarketinsights.com/ask-question/rep-gb-14876
Competitive landscape:
New market research report on epinephrine auto-injectors says that Adamis Pharmaceuticals Corporation, Alk-Abello A/S, Impax Laboratories, Inc., Mylan N.V., Antares Pharma is among the legacy player’s vendors.
The research offers a comprehensive competition analysis of these top competitors in the Global Epinephrine Auto Injectors Industry, including epinephrine auto-injectors market growth, epinephrine auto-injectors market share, epinephrine auto-injectors market adoption trends and important market strategies.
Recent Development in the Global Epinephrine Auto Injectors Industry:
- Antares Pharma (US) struck an arrangement with Lunatus Global Medical Supplies in August 2020. (Dubai). Antares will deliver packaged goods to Lunatus under this arrangement, and Lunatus will submit and get regulatory permission for XYOSTED in the UAE and Saudi Arabia, as well as promote, market, and distribute XYOSTED in these two countries.
- SHL Medical (Switzerland) bought Weibel CDS in March 2020. (Switzerland). The goal of this purchase was to increase SHL Medical’s capacity to develop more sophisticated medication delivery systems based on human-centered designs and functionality.
- Eli Lilly spent US$ 470 million and generated approximately 460 new jobs in Durham, NC in January 2020. With this extension, North Carolina’s research triangle park gained a new state-of-the-art pharmaceutical production plant.
Access Exclusive Market Insights – Purchase Now!
https://www.futuremarketinsights.com/checkout/14876
Key Segments:
By End-User:
- Hospitals
- Clinics
- Home Based
- Others
By Dosage:
- 0.15 mg
- 0.3 mg
- Others
By Age Group:
- 0-4 Years
- 5-14 Years
- 15-24 Years
- 25-49 Years
- 50-64 Years
- Above 65 Years
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube